跳到正文
小南AI实验室·· 23 天前AI 评分30

从文档到记录到智能:ISPE谈生命科学AI的企业级落地

从文档到记录到智能-ISPE谈生命科学AI的企业级落地

AI 导读

ISPE Pharmaceutical Engineering 的 iSpeak 文章提出,生命科学企业应把AI从个人生产力工具升级为企业级能力,前提是建立在可信、结构化且受治理的数字记录之上。文章梳理行业从文档数字化到结构化数字记录、再到AI应用的演进路径,并强调真正的挑战是建立治理模型、交付框架和决策结构,使创新能够负责任地规模化。

正文

洁净服检查员持文件夹与平板

制药现场的质量检查场景:洁净服检查员手持文件夹与平板电脑。该图为 ISPE 同栏目 10-28 文章题图。图源:ispe.org

2026-10-29 | 制药 AI 现场观察 | 主体材料:ISPE Pharmaceutical Engineering iSpeak,Shrikant Jodhwani(2026-10-27)

Every major transformation in life sciences has been built upon the foundations established by the one before it. The digitization of regulatory dossiers and enterprise documents created accessibility and transparency. The shift toward structured digital records enabled workflow automation, improved compliance, and data-driven decision-making. Now, the emergence of artificial intelligence (AI) is creating unprecedented opportunities to unlock value from the vast digital assets accumulated across the industry.

生命科学的每一次重大转型都建立在此前转型打下的地基之上。监管申报卷宗与企业文档的数字化带来了可及性与透明度。向结构化数字记录的迁移使工作流自动化成为可能,改善了合规,并支撑了数据驱动的决策。如今,人工智能(AI)的兴起正在创造前所未有的机会,从这个行业积累的海量数字资产中释放价值。

As organizations accelerate AI adoption, the conversation must extend beyond technology implementation. The real challenge is establishing governance models, delivery frameworks, and decision-making structures that allow innovation to scale responsibly. The organizations that succeed will be those that can combine scientific excellence, regulatory rigor, and AI-powered innovation through a framework of guided innovation.

随着各组织加快采用 AI,讨论必须超越技术实施本身。真正的挑战在于建立治理模型、交付框架和决策结构,让创新能够负责任地规模化。能够成功的组织,是那些能通过“引导式创新”框架把科学卓越、监管严谨与 AI 驱动的创新结合起来的组织。

The author still remembers one of his first projects in the life sciences industry.

作者至今仍记得自己在生命科学行业的最早几个项目之一。

At the time, the challenge was clear: regulatory submissions were created, reviewed, and managed across multiple functions, systems, and repositories. Teams were spending significant effort locating information, reconciling document versions, and coordinating communications with health authorities. The industry's focus was on digitizing submission dossiers and creating a single source of truth for regulatory content and correspondence throughout the drug development and approval lifecycle.

当时的挑战很明确:监管申报材料在多个职能、多个系统和多个知识库中被创建、审阅和管理。团队花费大量精力查找信息、核对文档版本、协调与卫生当局的沟通。行业的焦点是申报卷宗的数字化,以及在整个药物开发与批准生命周期内为监管内容和往来函件建立单一事实来源。

It was a transformational step.

那是一个变革性的步骤。

For the first time, organizations could move away from fragmented paper-based processes toward integrated digital repositories that connected regulatory affairs, quality, clinical, safety, and manufacturing functions. Information became more accessible, traceable, and reusable across the enterprise.

组织第一次得以摆脱碎片化的纸面流程,转向把注册事务、质量、临床、安全和制造职能连接起来的集成数字知识库。信息在企业范围内变得更易获取、可追溯、可复用。

However, this was only the beginning.

然而,这只是开始。

一、从文档到记录的迁移

The Shift from Documents to Records

As the industry matured in its digital transformation journey, a new realization emerged: digitizing documents was valuable, but digitizing information was far more powerful.

随着行业数字化转型之旅走向成熟,一种新的认识浮现:把文档数字化有价值,但把信息数字化要强大得多。

Organizations began breaking down large documents into structured digital records. Instead of managing entire documents as a single unit, individual pieces of information became first-class business objects.

各组织开始把大型文档拆解为结构化的数字记录。信息片段本身成为一等业务对象,而不再把整份文档当作单一管理单元。

For example, rather than maintaining a user requirements specification as a static document, individual requirements could be captured, governed, approved, traced, and reused as discrete records.

例如,用户需求规格(URS)不再作为静态文档来维护,其中的单条需求可以作为离散记录被采集、治理、批准、追踪和复用。

This seemingly simple shift had profound implications.

这个看似简单的转变有着深远的影响。

Workflows could now operate at the level of a single information object rather than an entire document package. Traceability improved significantly. Compliance became more transparent. Data quality increased through standardization and validation rules. Most importantly, organizations gained the ability to automate decisions and processes at a level that was previously impossible.

工作流现在可以运行在单个信息对象的层级,而不是整个文档包。可追溯性显著改善。合规变得更加透明。数据质量通过标准化和验证规则得到提升。最重要的是,组织获得了在以往不可能的层级上自动化决策与流程的能力。

The industry quietly transitioned from document-centric operations to record-centric operations.

行业悄然完成了从以文档为中心到以记录为中心的运营转型。

And in doing so, it laid the foundation for the next wave of transformation.

在此过程中,它为下一波转型奠定了基础。

生物药灌装产线洁净区

生物药灌装产线洁净区实景,数字化记录贯穿批次生产。图源:ispe.org(ISPE FOYA 2026 获奖设施照片)

二、为什么 AI 来得正是时候

Why AI Arrives at the Right Time

Today, AI stands at the doorstep of the life sciences industry.

今天,AI 已经站在生命科学行业的门口。

Much of the current discussion focuses on AI as a productivity tool: drafting content, summarizing information, generating insights, or assisting knowledge workers. These capabilities undoubtedly create value.

当前的大部分讨论把 AI 视为生产力工具:起草内容、汇总信息、生成洞察,或辅助知识工作者。这些能力无疑创造价值。

Yet the author believes the bigger opportunity lies elsewhere.

然而作者认为,更大的机会在别处。

AI is not merely seeking a role as a personal assistant.

AI 谋求的不只是一个个人助理的角色。

It is seeking promotion to become an enterprise capability.

它谋求的是“晋升”为一种企业级能力。

The true potential of AI emerges when it can operate across a landscape of trusted, structured, and governed digital records. The years invested in digitizing documents and subsequently transforming them into interconnected records have created the very foundation AI requires to deliver enterprise-scale value.

AI 的真正潜力,出现在它能够运行于一片可信、结构化且受治理的数字记录版图之上的时候。多年来把文档数字化、进而把它们转化为互相关联的记录的投入,恰好构成了 AI 交付企业级价值所需要的地基。

Across the drug lifecycle, AI has the potential to accelerate and enhance:

在整个药物生命周期中,AI 有潜力加速并增强:

- Research and target identification

- Clinical trial design and execution

- Regulatory authoring and submissions

- Quality management and compliance

- Pharmacovigilance operations

- Manufacturing and supply chain processes

· 研究与靶点识别

· 临床试验设计与执行

· 注册撰写与申报

· 质量管理与合规

· 药物警戒运营

· 制造与供应链流程

The industry's previous digital investments have paved the road for this opportunity. However, success will not be determined by technology alone.

行业此前的数字化投入已经为这个机会铺好了路。然而,成败不会只由技术决定。

三、治理的必要性

The Governance Imperative

As excitement around AI grows, organizations face a familiar challenge: how does the industry innovate rapidly while maintaining the rigorous standards expected within a highly regulated industry?

随着 AI 热度升温,组织面临一个熟悉的挑战:这个行业如何在保持高度监管行业所要求的严谨标准的同时,实现快速创新?

The answer is not unrestricted experimentation. Nor is it excessive bureaucracy.

答案不是不受约束的试验,也不是过度的官僚主义。

The answer lies somewhere in between.

答案介于两者之间。

Organizations need governance frameworks that provide clarity without creating friction. They need delivery methodologies that encourage innovation while ensuring patient safety, data integrity, compliance, and accountability.

组织需要既能提供清晰性又不制造摩擦的治理框架。它们需要既鼓励创新、又确保患者安全、数据完整性、合规与可问责性的交付方法。

In other words, they need guided innovation.

换句话说,它们需要引导式创新。

Guided innovation establishes the guardrails required for responsible adoption while preserving the creativity and speed necessary to unlock value.

引导式创新为负责任的采用设立护栏,同时保留释放价值所必需的创造力与速度。

This includes:

这包括:

- Clear AI governance structures and accountability models

- Risk-based assessment frameworks

- Defined stage gates across the AI development lifecycle

- Validation and monitoring approaches appropriate to AI-enabled solutions

- Data governance and model governance practices

- Compliance, ethics, and transparency standards

- Continuous performance measurement and oversight

· 清晰的 AI 治理结构与问责模型

· 基于风险的评估框架

· 贯穿 AI 开发生命周期的明确阶段关口

· 与 AI 解决方案相适应的验证与监测方法

· 数据治理与模型治理实践

· 合规、伦理与透明度标准

· 持续的绩效度量与监督

Just as software development matured through structured delivery methodologies, AI adoption will require its own evolution toward repeatable, scalable, and governable delivery frameworks.

正如软件开发通过结构化交付方法走向成熟,AI 的采用也需要自身的演进,走向可重复、可扩展、可治理的交付框架。

不锈钢工艺系统管路区

制药厂不锈钢工艺系统与自动化管路区实景。图源:ispe.org(ISPE FOYA 2026 获奖设施照片)

四、构建制药业的 AI 运营模型

Building the AI Operating Model for Pharma

The next strategic question facing life sciences leaders is not whether AI will create value. The question is how organizations will industrialize AI adoption responsibly.

生命科学领导者面临的下一个战略问题,不是 AI 能否创造价值,而是组织将如何负责任地把 AI 采用工业化。

Leading companies will move beyond isolated use cases and pilot programs. They will establish enterprise capabilities that integrate governance, methodology, technology, compliance, and business ownership into a coherent operating model.

领先企业将超越孤立的用例和试点项目。它们将建立把治理、方法论、技术、合规和业务归属整合为一个连贯运营模型的企业级能力。

This represents an important leadership opportunity.

这代表着一个重要的领导力机会。

The future of AI in life sciences will not be shaped solely by data scientists or technology teams. It will be shaped by leaders who can bridge innovation and compliance, speed and control, experimentation and accountability.

生命科学领域 AI 的未来不会只由数据科学家或技术团队塑造,而是由那些能够在创新与合规、速度与控制、试验与问责之间架起桥梁的领导者塑造。

Those leaders will help define how AI is developed, governed, validated, deployed, and continuously monitored across the organization.

这些领导者将参与定义 AI 在组织内如何被开发、治理、验证、部署和持续监测。

五、我们行业的激动时刻

An Exciting Time for Our Industry

Looking back, the progression feels remarkably logical. We began by digitizing documents. We then transformed those documents into structured digital records. Today, we stand ready to unlock intelligence from those records through AI. Each stage built upon the previous one.

回头看,这条演进路径有着清晰的逻辑。我们从文档数字化起步,然后把那些文档转化为结构化的数字记录。今天,我们已准备好通过 AI 从这些记录中释放智能。每一个阶段都建立在前一个阶段之上。

Each step increased the value of information.

每一步都提升了信息的价值。

And each transformation brought us closer to a future where knowledge can move faster than ever before across the drug lifecycle.

每一次转型都让我们更接近这样一个未来:知识在药物生命周期中的流动比以往任何时候都快。

For life sciences organizations, the opportunity is enormous. But realizing that opportunity will require more than innovative technology. It will require thoughtful governance, modern delivery methodologies, and a commitment to guided innovation.

对生命科学组织来说,机会巨大。但要把机会变成现实,仅靠创新技术不够。它还需要深思熟虑的治理、现代化的交付方法论,以及对引导式创新的坚持。

What an exciting time to be part of this journey.

能置身于这段旅程之中,是一个激动人心的时刻。

The next chapter of life sciences transformation is not simply about becoming more digital. It is about becoming intelligently digital.

生命科学转型的下一章,不只是变得更数字化,而是变得有智能地数字化。

资料来源:

原文:Shrikant Jodhwani,From Documents to Records to Intelligence: The Next Digital Frontier in Life Sciences,ISPE Pharmaceutical Engineering iSpeak Blog,2026-10-27

原文链接:https://ispe.org/pharmaceutical-engineering/ispeak/documents-records-intelligence-next-digital-frontier-life

来源:小南AI实验室 · mp.weixin.qq.com

所属事件

查看事件全部
ISPE文章提出生命科学AI需以受治理记录为基础